Infrequent methylation of CDKN2A(MTS 1p16) and rare mutation of both CDKN2A and CDKN2B(MTS2Ip15) in primary astrocytic tumours
1997

Methylation and Mutation Analysis of CDKN2A and CDKN2B in Astrocytic Tumors

Sample size: 70 publication Evidence: moderate

Author Information

Author(s): EE Schmidt, K Ichimura, KR Messerle, HM Goike, VP Collins

Primary Institution: Institute for Oncology and Pathology, Division of Tumour Pathology, and Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Hospital

Hypothesis

Loss of functional p16 and p15 proteins is involved in the progression of astrocytic tumors.

Conclusion

Point mutations of the CDKN2A and CDKN2B genes are infrequent, and hypermethylation of the CDKN2A gene does not appear to be a major mechanism for inhibiting its transcription in primary astrocytic tumors.

Supporting Evidence

  • One glioblastoma showed a missense mutation in exon 2 of CDKN2A.
  • None of the tumors retaining alleles of CDKN2B showed mutations.
  • Hypermethylation of the CDKN2A gene is infrequent in astrocytic gliomas.

Takeaway

The study looked at brain tumors and found that changes in certain genes are not very common, which means other factors might be causing the tumors.

Methodology

The study involved sequencing the coding regions and splice sites of CDKN2A and CDKN2B in 70 tumors, including glioblastomas, anaplastic astrocytomas, and astrocytomas.

Limitations

The presence of normal cells in tumor samples complicates the interpretation of expression studies.

Participant Demographics

The study included 46 glioblastomas, 16 anaplastic astrocytomas, and 8 astrocytomas.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication